These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 31069898)

  • 1. Clinical advances of siRNA therapeutics.
    Hu B; Weng Y; Xia XH; Liang XJ; Huang Y
    J Gene Med; 2019 Jul; 21(7):e3097. PubMed ID: 31069898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNAi therapeutic and its innovative biotechnological evolution.
    Weng Y; Xiao H; Zhang J; Liang XJ; Huang Y
    Biotechnol Adv; 2019; 37(5):801-825. PubMed ID: 31034960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. siRNA therapeutics: a clinical reality.
    Saw PE; Song EW
    Sci China Life Sci; 2020 Apr; 63(4):485-500. PubMed ID: 31054052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leading RNA Interference Therapeutics Part 1: Silencing Hereditary Transthyretin Amyloidosis, with a Focus on Patisiran.
    Titze-de-Almeida SS; Brandão PRP; Faber I; Titze-de-Almeida R
    Mol Diagn Ther; 2020 Feb; 24(1):49-59. PubMed ID: 31701435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of siRNA Therapeutics for the Treatment of Liver Diseases.
    Holm A; Løvendorf MB; Kauppinen S
    Methods Mol Biol; 2021; 2282():57-75. PubMed ID: 33928570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Journey of siRNA: Clinical Developments and Targeted Delivery.
    Nikam RR; Gore KR
    Nucleic Acid Ther; 2018 Aug; 28(4):209-224. PubMed ID: 29584585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The current state and future directions of RNAi-based therapeutics.
    Setten RL; Rossi JJ; Han SP
    Nat Rev Drug Discov; 2019 Jun; 18(6):421-446. PubMed ID: 30846871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic siRNA: state of the art.
    Hu B; Zhong L; Weng Y; Peng L; Huang Y; Zhao Y; Liang XJ
    Signal Transduct Target Ther; 2020 Jun; 5(1):101. PubMed ID: 32561705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA interference (RNAi) in hematology.
    Scherr M; Steinmann D; Eder M
    Ann Hematol; 2004 Jan; 83(1):1-8. PubMed ID: 14574462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bio-inspired materials in drug delivery: Exploring the role of pulmonary surfactant in siRNA inhalation therapy.
    De Backer L; Cerrada A; Pérez-Gil J; De Smedt SC; Raemdonck K
    J Control Release; 2015 Dec; 220(Pt B):642-50. PubMed ID: 26363301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. siRNA based drug design, quality, delivery and clinical translation.
    Subhan MA; Torchilin VP
    Nanomedicine; 2020 Oct; 29():102239. PubMed ID: 32544449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo application of RNA interference: from functional genomics to therapeutics.
    Lu PY; Xie F; Woodle MC
    Adv Genet; 2005; 54():117-42. PubMed ID: 16096010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. To Conjugate or to Package? A Look at Targeted siRNA Delivery Through Folate Receptors.
    Salim L; Desaulniers JP
    Nucleic Acid Ther; 2021 Feb; 31(1):21-38. PubMed ID: 33121373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies.
    Traber GM; Yu AM
    J Pharmacol Exp Ther; 2023 Jan; 384(1):133-154. PubMed ID: 35680378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of new RNAi therapeutics.
    Liu G; Wong-Staal F; Li QX
    Histol Histopathol; 2007 Feb; 22(2):211-7. PubMed ID: 17149694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RNA interference therapeutics for cancer: challenges and opportunities (review).
    Bora RS; Gupta D; Mukkur TK; Saini KS
    Mol Med Rep; 2012 Jul; 6(1):9-15. PubMed ID: 22576734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene Silencing using siRNA for Preventing Liver Ischaemia-Reperfusion Injury.
    Marinho HS; Marcelino P; Soares H; Corvo ML
    Curr Pharm Des; 2018; 24(23):2692-2700. PubMed ID: 30084326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming obstacles to develop effective and safe siRNA therapeutics.
    Li L; Shen Y
    Expert Opin Biol Ther; 2009 May; 9(5):609-19. PubMed ID: 19392577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNA interference technology with emphasis on delivery vehicles-prospects and limitations.
    Prabha S; Vyas R; Gupta N; Ahmed B; Chandra R; Nimesh S
    Artif Cells Nanomed Biotechnol; 2016 Sep; 44(6):1391-9. PubMed ID: 26140615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. siRNA delivery by a transferrin-associated lipid-based vector: a non-viral strategy to mediate gene silencing.
    Cardoso AL; Simões S; de Almeida LP; Pelisek J; Culmsee C; Wagner E; Pedroso de Lima MC
    J Gene Med; 2007 Mar; 9(3):170-83. PubMed ID: 17351968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.